Longitudinal immune cell monitoring identified CD14++ CD16+ intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis.
Kotaro MatsumotoKatsuya SuzukiKeiko YoshimotoNoriyasu SekiHideto TsujimotoKenji ChibaTsutomu TakeuchiPublished in: Arthritis research & therapy (2020)
Chronological changes in CD14++ CD16+ intermediate monocyte counts can be a marker of disease relapse in AAV patients.